Elucidating the secretion proteome of human
Only some of the various studies using CM checked the growth factor levels (Table 3) [5–10, 13, 17, 20, 22, 24, 25, 27, 28, 33, 36] and the same type of cells yielded different growth factor levels, when cell number, culture medium and condition, and CM processing were different [6, 24].Moreover, growth factor measures also differed, that is, pg/m L or ng/m L [6, 8, 10, 13, 17, 24, 27, 28, 33], pg/μg DNA [9, 36], fg/cell , spot density , and positive/negative  (Table 3). This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Department of Histology, Faculty of Medicine, University of Indonesia, Jalan Salemba 6, Jakarta 10430, Indonesia Received ; Revised 22 July 2014; Accepted 25 July 2014; Published 28 August 2014Academic Editor: Antonio Salgado Copyright © 2014 Jeanne Adiwinata Pawitan. However, the various CM, even when they were derived from the same kind of cells, were produced by different condition, that is, from different passage, culture medium, and culture condition.The use of CM for therapy is very appealing and may be booming in the near future, as studies on the use of CM for various diseases are accumulating [1, 3–33].
However, standardized methods of production and validations of their use need to be conducted.
Therefore, stem cell-derived conditioned medium have a promising prospect to be produced as pharmaceuticals for regenerative medicine.
To date, no clinical trial that used CM for a certain disease has been reported, except two pilot studies on the use of adipose derived mesenchymal stem cell CM for hair follicle regeneration  and fractional carbon dioxide resurfacing wound healing  in human, which showed good results.
Various studies showed that conditioned medium have been tested in various kinds of diseases/conditions (Table 1) [1, 3–33], that is, alopecia [3, 5], acute and chronic hind limb ischemia [6–9], acute and chronic wound healing [4, 10–14], myocardial infarct [1, 15–18], acute liver injury/failure [19–22], cerebral injury/ischemia/stroke [23–27], spinal cord injury , lung injury , and bone defect , and showed improvement of the conditions.
Moreover, chronic kidney disease that was treated using human embryonic stem cell-derived mesenchymal stem cell (hu ESC-MSC) CM showed decreased systolic blood pressure and proteinuria and improvement in tubular and glomerular damage, renal blood flow, and glomerular filtration rate .
Data collection is as follows: treated conditions/diseases, type of cell that was cultured, detailed composition of medium and supplements that was used to culture the cells, culture condition (hypoxia or normoxia) to get the CM, CM processing, growth factors, and other secretions that were analyzed; method (mode) of application and outcome of CM application were noted, grouped, and tabulated.